中西医干预肝癌患者血小板无效输注的研究进展  

Research progress of Chinese and western medicine intervention on platelet transfusion refractoriness in patients with liver cancer

作　　者：农耀斌 黄鸿娜[2] 黄晶晶[3] 董芷辛 宋文选 肖熹煜 杜沅沁 NONG Yaobin;HUANG Hongna;HUANG Jingjing;DONG Zhixin;SONG Wenxuan;XIAO Xiyu;DU Yuanqin(Graduate School,Guangxi University of Chinese Medicine,Guangxi Zhuang Autonomous Region,Nanning530022,China;Teaching and Research Section of Internal Medicine of Chinese Medicine,the First Affiliated Hospital of Guangxi University of Chinese Medicine,Guangxi Zhuang Autonomous Region,Nanning530022,China;Department of Lienal,Gastric,and Hepatic Disease,Xianhu Branch of the First Affiliated Hospital of Guangxi University of Chinese Medicine,Guangxi Zhuang Autonomous Region,Nanning530022,China;Ward Two,Department of Oncology,Xianhu Branch of the First Affiliated Hospital of Guangxi University of Chinese Medicine,Guangxi Zhuang Autonomous Region,Nanning530022,China)

机构地区：[1]广西中医药大学研究生学院,广西南宁530022 [2]广西中医药大学第一附属医院中医内科教研室,广西南宁530022 [3]广西中医药大学第一附属医院仙葫院区脾胃肝病科,广西南宁530022 [4]广西中医药大学第一附属医院仙葫院区肿瘤科二区,广西南宁530022

出　　处：《中国医药导报》2023年第3期41-44,共4页China Medical Herald

基　　金：国家自然科学基金支持项目(81760845);广西高校中青年教师科研基础能力提升项目(2019KY0313);广西研究生教育创新计划项目(YCXJ2021056、YCBSY2020007)。

摘　　要：肝癌的发生常由病毒性肝炎、肝硬化、黄曲霉毒素污染等进展演变而来,大部分肝癌患者合并有脾功能亢进,导致其血小板在外周血中有不同程度的减少,同时靶向药物治疗会对巨核细胞、骨髓功能等产生强烈的抑制作用,也可使血小板数量减少。在肝癌患者血小板输注治疗中可能会出现多次输注无法达到理想效果的情况,出血状态也未得到缓解,甚至发生血小板无效输注(PTR)。肝癌患者异常出血与血小板水平息息相关,因此,探讨中西医调控血小板对肝癌患者PTR治疗至关重要。本文将血小板的生成、肝癌患者PTR机制、中西医调控干预措施进行简要综述,为肝癌患者PTR的临床治疗提供参考,拓宽治疗思路。The occurrence of liver cancer is often evolved from the progression of viral hepatitis, cirrhosis, aflatoxin contamination, and so on. Most patients with liver cancer are complicated with hyperplenism, which leads to the reduction of their platelets in peripheral blood to varying degrees. At the same time, targeted drug therapy can produce strong inhibition on megakaryocytes and bone marrow function, and can also lead to a decrease in the number of platelets. In the treatment of platelet transfusion in patients with liver cancer, there may be several times of infusion but the ideal effect can not be achieved, the bleeding status is not alleviated, and even platelet transfusion refractoriness(PTR) occurs. Abnormal bleeding in patients with liver cancer is closely related to platelets level. Therefore, it is very important to explore the regulation of platelets by Chinese and western medicine in the treatment of PTR in patients with liver cancer. In this paper, platelet generation, PTR mechanism in patients with liver cancer, regulation and intervention measures of Chinese and western medicine are briefly reviewed, so as to provide reference for the clinical treatment of PTR in patients with liver cancer and broaden treatment ideas.

关 键 词：肝癌 血小板 血小板无效输注 中医 西医 

分 类 号：R457.1[医药卫生—治疗学]